Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Stage IV Gastric Cancer
Interventions
DRUG

Paclitaxel

Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

DRUG

Paclitaxel

Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

Trial Locations (13)

612-896

Inje University Haeundae Paik Hospital, Busan

702-210

Kyungpook National University Medical Center, Daegu

410-769

National Cancer Center, Goyang-si

519-763

Chonnam National University Hwasun Hospital, Jungnam

Unknown

Seoul National University Bundang Hospital, Seongnam-si

120-752

Yonsei University Severance Hospital, Seoul

135-710

Samsung Medical Center, Seoul

135-720

Yonsei University Gangnam Severance Hospital, Seoul

137-701

Seoul St. Mary's Hospital, Seoul

138-736

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Asan Medical Center, Seoul

152-703

Korea University Guro Hospital, Seoul

443-380

Ajou University Hospital, Suwon

All Listed Sponsors
lead

Daehwa Pharmaceutical Co., Ltd.

INDUSTRY

NCT01839773 - Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer | Biotech Hunter | Biotech Hunter